利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

801 条记录 (耗时 0.037 秒)

    A HYBRID CELL VACCINE AGAINST LEISHMANIASIS [KALA-AZAR]
    74.
    发明授权
    A HYBRID CELL VACCINE AGAINST LEISHMANIASIS [KALA-AZAR] 有权
    杂交细胞疫苗抗利什曼病黑热病

    公开(公告)号：EP2037958B1

    公开(公告)日：2012-02-01

    申请号：EP07766931.5

    申请日：2007-06-15

    申请人： Council of Scientific and Industrial Research

    发明人： BHAUMIK, Suniti ,  BASU, Rajatava ,  NASKAR, Kshudiram ,  ROY, Syamal

    IPC分类号： A61K39/008 ,  C12N5/16 ,  A61P33/02

    CPC分类号： A61K39/008 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/545 ,  C12N5/16 ,  Y02A50/41

    摘要： The present invention provides a hybrid cell vaccine against Leishmaniasis comprising of syngeneic macrophage with a dominant Leishmania antigen-KMP-11 electrofused with allogenic Dendritic Cell. Hybrid cell vaccination approach with dendritic cells has been widely used successfully in tumor models only. By devising a novel strategy of transfecting syngeneic macrophage cell line from BALB/c mice with a dominant Leishmania antigen-KMP-11 and electrofusing with allogenic DC from C57BLJ6, the inventors obtained a complete clearance of splenic and hepatic parasite burden in late stage L. donovani infection in genetically susceptible BALB/c mice. Curative response resulted from a high KMP-11 specific MHC class I restricted CD8*CTL response. This is the first study that realized the potential of hybrid cell vaccine in the field of infectious disease and clearly shows the contribution of Th2 cytokine response in conferring protection to Leishmania donovani infection in experimental VL model.

    USE OF 5-HYDROXY-2-HYDROXYMETHYL- Y -PYRONE (HMP) AS A LEISHMANICIDAL AGENT
    78.
    发明公开
    USE OF 5-HYDROXY-2-HYDROXYMETHYL- Y -PYRONE (HMP) AS A LEISHMANICIDAL AGENT 有权
    5-羟基-2-羟甲基-γ-吡喃酮（HMP）作为杀虫剂的用途

    公开(公告)号：EP2337560A1

    公开(公告)日：2011-06-29

    申请号：EP09806250.8

    申请日：2009-08-14

    申请人： Universidade Federal Do Pará

    发明人： SANTOS, Alberdan Silva ,  SILVA, Edilene Oliveira da ,  NASCIMENTO, José Luiz Martins do ,  ALVES, Cláudio Naum ,  RODRIGUES, Ana Paula Drumond ,  CARVALHO, Antônio Sérgio da Costa

    IPC分类号： A61K31/351 ,  A61P33/02

    CPC分类号： C07D309/40 ,  A61K31/351 ,  A61K31/366 ,  Y02A50/409

    摘要： The present invention refers to the use of HMP (a secondary metabolite obtained from Aspergillus fungi) as an agent that intensifies the mechanism of macrophage activation, leading to the death of L. (Leishmania) amazonensis, the etiologic agent of cutaneous leishmaniasis. The main mechanism of action of this agent is the activation of the microbicidal activity of host cells, through increased superoxide production, number of lysosomes, actin and microtubule filament polymerization and increased spreading, typical of activated cells. Additionally, HMP represents a molecule of easy acquisition, presents an efficient combat mechanism with no adverse reactions and capacity to inhibit the development of promastigotes and amastigotes forms. Finally, results suggest HMP to be a potential candidate for use against cutaneous leishmaniasis at a minimal concentration of 50 μg/mL.

    摘要翻译： 本发明涉及使用HMP（从曲霉属真菌获得的次级代谢物）作为增强巨噬细胞活化机制的药剂，导致L.（利什曼原虫）亚马逊杆菌（皮肤利什曼病的病原体）的死亡。 该作用剂的主要作用机理是通过增加超氧化物的产生，溶酶体的数量，肌动蛋白和微管丝聚合以及活化细胞的典型增加的扩散来激活宿主细胞的杀微生物活性。 此外，HMP代表了一种容易获得的分子，呈现出高效的作战机制，没有不良反应，并且具有抑制前鞭毛体和无鞭毛体形式发育的能力。 最后，结果表明HMP是在50μg/ mL的最低浓度下用于抵抗皮肤利什曼病的潜在候选物。

    Pharmaceutical composition containing cannabinoid-receptor 2 antagonists
    79.
    发明公开
    Pharmaceutical composition containing cannabinoid-receptor 2 antagonists 审中-公开
    Pharmazutische Zusammensetzung mit Cannabinoid 2-Rezeptorantagonisten

    公开(公告)号：EP2311443A1

    公开(公告)日：2011-04-20

    申请号：EP09013039.4

    申请日：2009-10-15

    申请人： Rheinische Friedrich-Wilhelms-Universität

    发明人： Alferink, Judith ,  Zimmer, Andreas ,  Hörauf, Achim ,  Specht, Sabine

    IPC分类号： A61K31/00 ,  A61K31/357 ,  A61K31/415 ,  A61K31/4706 ,  A61K31/49 ,  A61K45/06 ,  A61P33/00 ,  A61P33/02 ,  A61P33/08

    CPC分类号： A61K31/415 ,  A61K31/00 ,  A61K31/122 ,  A61K31/137 ,  A61K31/155 ,  A61K31/357 ,  A61K31/47 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/49 ,  A61K31/505 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/635 ,  A61K45/06 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  A61K2300/00

    摘要： The present invention relates to the use of cannabinoid-receptor 2 (CB 2 R)-antagonists for the prophylaxis and/or treatment of pathogen, in particular, parasitic protozoa, caused or induced cerebral diseases, disorders or conditions including secondary and accompanying diseases, disorders or conditions, like encephalitis. In a preferred embodiment, said CB 2 R-antagonist is a 3-pyrazole-carboxamide derivative. In a further aspect, the present invention provides pharmaceutical compositions comprising said CB 2 R-antagonist in combination with an anti-pathogenic active ingredient, optionally together with pharmaceutically acceptable carriers, diluents and/or excipients. Said pharmaceutical compositions are useful for treating encephalitis, like cerebral malaria induced by Plasmodium falciparum. Thus, in another aspect, methods for the treatment of pathogen, like parasitic protozoa induced or caused cerebral diseases, disorders or conditions including encephalitis, in particular cerebral malaria are provided comprising the steps of administering a CB 2 R-receptor antagonist.

    摘要翻译： 本发明涉及大麻素 - 受体2（CB 2 R） - 拮抗剂用于预防和/或治疗病原体，特别是寄生原虫，引起或引起的脑疾病，病症或病症，包括继发性和伴随疾病， 疾病或病症，如脑炎。 在优选的实施方案中，所述CB 2 R-拮抗剂是3-吡唑 - 甲酰胺衍生物。 在另一方面，本发明提供药物组合物，其包含所述CB 2 R-拮抗剂与抗病原活性成分，任选与药学上可接受的载体，稀释剂和/或赋形剂组合。 所述药物组合物可用于治疗脑炎，如恶性疟原虫引起的脑疟疾。 因此，在另一方面，提供了用于治疗病原体的方法，例如诱导或引起的脑疾病，疾病或病症，包括脑炎，特别是脑疟疾的寄生原生动物，包括施用CB 2 R受体拮抗剂的步骤。